Your browser doesn't support javascript.
loading
Oligoclonal IgM bands are a promising biomarker for long-term cognitive outcomes in multiple sclerosis.
Coll-Martinez, Clàudia; Quintana, Ester; Buxó, Maria; Salavedra-Pont, Judit; Gasull-Vicens, Laia; Quiroga-Varela, Ana; Costa-Frossard, Lucienne; Villar, Luisa María; Fernández-Díaz, Eva; Gracia, Julia; Aladro, Yolanda; Méndez-Burgos, Alejandro; Cerezo, Marta; Ramió-Torrentà, Lluís; Gich, Jordi.
Afiliação
  • Coll-Martinez C; Girona Neuroimmumology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Dr Castany s/n, Girona, Salt 17190, Spain; Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Salt, Spain; R
  • Quintana E; Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Salt, Spain.
  • Buxó M; Girona Biomedical Research Institute (IDIBGI), Salt, Spain.
  • Salavedra-Pont J; Girona Neuroimmumology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Dr Castany s/n, Girona, Salt 17190, Spain; Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Salt, Spain.
  • Gasull-Vicens L; Girona Neuroimmumology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Dr Castany s/n, Girona, Salt 17190, Spain.
  • Quiroga-Varela A; Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Salt, Spain; Redes de Investigación Cooperativa Orientada a Resultados en Salud (RICORS), Red de Enfermedades inflamatorias (RD21/0002/0063), Instituto de Salud Carlos III, Madrid, Spain.
  • Costa-Frossard L; Redes de Investigación Cooperativa Orientada a Resultados en Salud (RICORS), Red de Enfermedades inflamatorias (RD21/0002/0063), Instituto de Salud Carlos III, Madrid, Spain; Neurology Department, Ramon y Cajal University Hospital, Madrid, Spain; Universidad de Alcalá, Madrid, Spain; Multiple Sclero
  • Villar LM; Redes de Investigación Cooperativa Orientada a Resultados en Salud (RICORS), Red de Enfermedades inflamatorias (RD21/0002/0063), Instituto de Salud Carlos III, Madrid, Spain; Multiple Sclerosis Group, Instituto Ramón y Cajal de investigación Sanitaria (IRYCIS), Madrid, Spain; Immunology Department,
  • Fernández-Díaz E; Neurology Department, Albacete University Hospital Albacete, Spain.
  • Gracia J; Neurology Department, Albacete University Hospital Albacete, Spain.
  • Aladro Y; Redes de Investigación Cooperativa Orientada a Resultados en Salud (RICORS), Red de Enfermedades inflamatorias (RD21/0002/0063), Instituto de Salud Carlos III, Madrid, Spain; Neurology Department, Getafe University Hospital, Madrid, Spain; Universidad Europea de Madrid, Madrid, Spain.
  • Méndez-Burgos A; Neurology Department, Getafe University Hospital, Madrid, Spain; Universidad Europea de Madrid, Madrid, Spain.
  • Cerezo M; Neurology Department, Getafe University Hospital, Madrid, Spain; Universidad Complutense de Madrid, Madrid, Spain.
  • Ramió-Torrentà L; Girona Neuroimmumology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Dr Castany s/n, Girona, Salt 17190, Spain; Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Salt, Spain; R
  • Gich J; Girona Neuroimmumology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital, Dr Castany s/n, Girona, Salt 17190, Spain; Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Salt, Spain; M
Mult Scler Relat Disord ; 68: 104397, 2022 Dec.
Article em En | MEDLINE | ID: mdl-36544326
ABSTRACT

BACKGROUND:

The presence of lipid-specific oligoclonal IgM bands (LS-OCMB) in cerebrospinal fluid is associated with a more severe clinical multiple sclerosis (MS) course.

OBJECTIVE:

To investigate LS-OCMB as a prognostic biomarker of cognitive long-term outcomes in MS.

METHODS:

Ninety-nine patients underwent neuropsychological assessment. Cognitive performance between LS-OCMB- and LS-OCMB+ patients was compared adjusting by age, education, anxiety-depression, disease duration, and disability.

RESULTS:

LS-OCMB+ patients of ∼13 years of disease duration performed worse on Symbol Digit Modalities Test (SDMT) (p = 0.005).

CONCLUSION:

LS-OCMB+ perform worse on information processing speed and working memory (SDMT), suggesting that LS-OCMB could be a useful biomarker for long-term cognitive outcomes.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Idioma: En Ano de publicação: 2022 Tipo de documento: Article